Hyperice Introduces Virgil van Dijk as Athlete Ambassador
2.10.2025 16:00:00 EEST | Business Wire | Press release
Hyperice, the global leader in high-performance wellness technology, today announced Dutch international and Liverpool FC Defender and Captain Virgil van Dijk as its newest athlete ambassador.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251002549534/en/
As a regular user of Hyperice products - having used Normatec for his post-match recovery for years - van Dijk has partnered with the brand to highlight the importance of recovery and performance innovation.
The announcement coincides with the UK and European launch of the Nike x Hyperice Hyperboot - the wearable and mobile innovation designed to accelerate warm-up and recovery used by the world’s top athletes including van Dijk, Sha’Carri Richardson, Jayden Daniels, and more - available to consumers for the first time in the UK, Europe and Canada from October 2nd.
As a regular user of Hyperice products - having used Normatec for his post-match recovery for years - van Dijk has partnered with the brand to highlight the importance of recovery and performance innovation. With the physical demands of playing in the Premier League and Champions League, managing fatigue, reducing muscle soreness, and optimising readiness between matches, Hyperice is crucial to sustaining peak performance.
Compression therapy, heat, percussion massage and targeted recovery tools have become essential for players competing at the highest level, and Hyperice is leading the way in delivering these solutions.
The Hyperboot by Nike x Hyperice is a groundbreaking innovation that combines heat and Normatec dynamic air compression, redefining how athletes prepare and recover. The Hyperboot provides a fully mobile, high-top solution that supports footballers and athletes at every stage of their journey, helping them through long travel days, pre-match warm-ups, and enabling them to perform at the highest level.
“Virgil is a world-class athlete who embodies resilience and leadership at the highest level of sport,” said Steph Smith, VP of Marketing at Hyperice. “As we bring the Hyperboot to the UK and Europe, his dedication to football and relentless pursuit of excellence both on and off the pitch make him the perfect partner to showcase the power of innovation in recovery and performance.”
Commenting on the partnership, Virgil van Dijk said: “Recovery is such an important part of my routine, and Hyperice products have always been at the centre of it. I’ve been an avid user of the Normatec boots for years, often using them post-match and training.”
“The Hyperboot has been a real advancement in performance technology, particularly being able to walk around whilst starting the warm-up process before a training session or match. It’s become an extension of the routine I’ve had for years using products like Normatec to help ensure I’m always at my best,” said van Dijk. “For me, warm up and recovery are just as important as the training itself, so I’m proud to work with Hyperice and use the best products to help me stay at the top of my game.”
The Hyperboot by Nike x Hyperice will be available in the UK and Europe at nike.com and hyperice.com for €749.99/ £699.99, as well as Canada at hyperice.com for CA$1199.00.
IMAGERY HERE
Notes to Editors
About the Hyperboot
Nike and Hyperice have taken warm-up and recovery to the next level with the Hyperboot, a wearable and mobile footwear innovation designed to help athletes perform at their best throughout training and competition.
The Hyperboot contains a system of dual-air bladders that deliver sequential compression patterns and are bonded to thermally efficient heating elements that evenly distribute heat throughout the shoe’s entire upper. This combination, enabled by Hyperice’s Normatec line and the brand’s HyperHeat technology, is designed to drive heat deep into the muscle and tissue in the foot and ankle, helping athletes move, perform and recover faster.
The Hyperboot will be released on 2 October in the UK and Europe and will retail for €749.99/ £699.99. The Hyperboot will be available at nike.com, hyperice.com and for try-on at Nike House of Innovation Paris and Nike Oxford Circus.
About Hyperice
Hyperice, the global leader in high-performance wellness technology, is a technology-driven company with a giant mission: to help everyone on Earth move and live better. For more than a decade, Hyperice has led a global movement at the confluence of recovery and wellness, specialising in percussion (Hypervolt line), dynamic air compression (Normatec line), vibration (Vyper and Hypersphere lines), thermal technology (Venom line), contrast therapy (Hyperice X), and Hyperboot collaboration with Nike.
Now, as a holistic high-performance wellness brand, Hyperice is designed for all, from the most elite athletes, leagues, and teams to consumers everywhere looking to unlock the best version of themselves to help them do what they love, more. Recognised as one of Fast Company’s Most Innovative Companies and a TIME Best Inventions winner, Hyperice has applied its technology and know-how to industries including fitness, hospitality, healthcare, massage, physiotherapy, sports performance, and workplace wellness on a global scale. For more information, visit hyperice.com.
About Virgil van Dijk
Virgil van Dijk is a Dutch professional footballer who captains Liverpool Football Club and the Netherlands national team. The centre back is considered one of the best defenders in the game and has won the Premier League twice with Liverpool as well as the Champions League. Before joining Liverpool, he played for Southampton, Celtic and FC Groningen.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251002549534/en/
Contacts
MEDIA CONTACT:
Fittest PR
hyperice@fittestpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom